Valuation : Lupin Limited

Market Cap 958B 10.03B 8.64B 8.18B 7.42B 13.92B 13.99B 97.2B 37.38B 488B 37.67B 36.85B 1,541B P/E 2027 *
21.8x
P/E 2028 * 20.4x
Enterprise Value 918B 9.61B 8.28B 7.84B 7.1B 13.33B 13.39B 93.07B 35.79B 467B 36.07B 35.28B 1,475B EV / Sales 2027 *
3.03x
EV / Sales 2028 * 2.73x
Free-Float
52.98%
Yield 2027 *
0.61%
Yield 2028 * 0.62%
1 day+0.83%
1 week-0.71%
Current month-4.27%
1 month-8.07%
3 months-7.84%
6 months-10.65%
Current year-0.69%
1 week 2,058
Extreme 2058
2,135.5
1 month 2,058
Extreme 2058
2,278
Current year 2,058
Extreme 2058
2,529.5
1 year 1,900
Extreme 1900
2,529.5
3 years 1,091.5
Extreme 1091.5
2,529.5
5 years 583
Extreme 583
2,529.5
10 years 504.75
Extreme 504.75
2,529.5
Manager TitleAgeSince
Chief Executive Officer 58 01/09/2013
Director of Finance/CFO 61 13/08/2007
Compliance Officer - 01/09/2024
Director TitleAgeSince
Director/Board Member 52 08/10/2008
Director/Board Member 58 01/01/1997
Chairman 83 11/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.83%-0.71% - - 10.03B
-0.65%-2.93%+47.52%+87.34% 994B
-0.29%-3.51%+48.78%+63.27% 640B
+0.83%+0.26%+16.76%+72.52% 454B
-0.38%-3.59%+28.24%+35.57% 337B
-0.09%-13.54%+10.08%+26.87% 261B
-0.43%-2.48%-2.07%+11.48% 246B
-1.34%-13.70%+33.47%+44.18% 204B
-3.44%-7.51%-20.08%-59.58% 190B
-0.75%-4.82%+21.94%+86.55% 178B
Average -0.57%-5.76%+20.52%+40.91% 389.42B
Weighted average by Cap. -0.51%-4.42%+29.87%+55.71%

Financials

2027 *2028 *
Net sales 303B 3.17B 2.73B 2.59B 2.34B 4.4B 4.42B 30.72B 11.81B 154B 11.91B 11.65B 487B 323B 3.38B 2.91B 2.76B 2.5B 4.69B 4.71B 32.75B 12.6B 164B 12.7B 12.42B 519B
Net income 44.04B 461M 397M 376M 341M 640M 643M 4.47B 1.72B 22.41B 1.73B 1.69B 70.8B 46.93B 491M 423M 401M 363M 682M 685M 4.76B 1.83B 23.88B 1.84B 1.8B 75.45B
Net Debt -40.7B -426M -367M -348M -315M -591M -594M -4.13B -1.59B -20.71B -1.6B -1.56B -65.43B -75.52B -791M -681M -645M -585M -1.1B -1.1B -7.66B -2.95B -38.42B -2.97B -2.9B -121B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
11/09/26 ₹2,095.00 +0.83% 621,899
10/09/26 ₹2,077.80 -1.06% 624,838
09/09/26 ₹2,100.00 -0.22% 596,996
08/09/26 ₹2,104.70 -0.01% 713,131
07/09/26 ₹2,105.00 -0.24% 819,621
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
2,096.00INR
Average target price
2,490.58INR
Spread / Average Target
+18.83%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!